Press Briefing EHA22

| Abstract S100. QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML
Dr Harry Erba, Duke University, Durham, NC, USA

| Abstract S125. 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY (“3+7”) FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG
Dr Micheal Lübbert, Universitätsklinikum Freiburg, Freiburg, Germany

| Abstract S103. EFFICACY AND SAFETY OF ARI0002H, AN ACADEMIC BCMA-DIRECTED CAR-T CELL THERAPY WITH FRACTIONATED INITIAL THERAPY AND BOOSTER DOSE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Fernandez De C. 06/11/22; 356968; S103, Hospital Clínic de Barcelona, Barcelona, Spain

| Abstract S209 (the abstract was presented at ASCO 2022). PRIMARY RESULTS FROM THE PHASE 3 SHINE STUDY OF IBRUTINIB IN COMBINATION WITH BENDAMUSTINE- RITUXIMAB (BR) AND R MAINTENANCE AS A FIRST-LINE TREATMENT FOR OLDER PATIENTS WITH MANTLE-CELL LYMPHOMA

Dr Michael L. Wang, The University of Texas MD Anderson Cancer Center, Houston, TX,

| Abstract S104. RBPS DYSREGULATION CAUSE HYPER-NUCLEOLI AND RIBOSOME GAIN-OF-FUNCTION DRIVING BONE MARROW FAILURE

Aguilar-Garrido P. 06/11/22; 356969; S104, Centro Nacional de Investigaciones Oncólogicas, Madrid, Spain

| Late Breaking Abstract LB2365. TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PFS CO-PRIMARY ENDPOINT OF THE RANDOMIZED PHASE 3 GAIA/CLL13 TRIAL
Dr Barbara Eichhorst, The University of Cologne, Cologne, Germany (Zusammenfassung Abstract)

| Late Breaking Abstract LB2367: EFFICACY AND SAFETY OF A SINGLE DOSE OF CTX001 FOR TRANSFUSION-DEPENDENT ΒETATHALASSEMIA AND SEVERE SICKLE CELL DISEASE
Dr Franco Locatelli, Sapienza, University of Rome, Rome, Italy